Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

interlacemedical.com

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$26.25M

Valuation

$0000 

About Interlace Medical

Interlace Medical Corporation designs and develops minimally invasive devices for the gynecological surgeon to aid them in removal of uterine fibroids and polyps.

Interlace Medical Headquarters Location

139 Newbury Street

Framingham, Massachusetts, 01701,

United States

508-875-1343

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Interlace Medical Patents

Interlace Medical has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/7/2007

7/27/2010

Robotics, Robots, Healthcare occupations, Medical ethics, Medical terminology

Grant

Application Date

9/7/2007

Grant Date

7/27/2010

Title

Related Topics

Robotics, Robots, Healthcare occupations, Medical ethics, Medical terminology

Status

Grant

Latest Interlace Medical News

U.S. Patent Office nixes Smith & Nephew patents in spat with Hologic

Feb 7, 2014

February 7, 2014 by Brad Perriello The U.S. Patent & Trademark Office nixes 2 patents at issue in Smith & Nephew's long-running infringement battle with Interlace Medical and subsequent acquirer Hologic. The U.S. Patent & Trademark Office dealt a setback to Smith & Nephew (FTSE: SN , NYSE: SNN ) last month when it invalidated claims in a pair of patents at the core of a long-running infringement dispute with Interlace Medical and its subsequent acquirer, Hologic  (NSDQ: HOLX ). Smith & Nephew sued Interlace in 2010, alleging infringement of a pair of patents with the MyoSure fibroid tumor device, and filed against Hologic after the Interlace buyout in January 2011. Sign up to get our free newsletters delivered right to your inbox. In September 2012, a jury  awarded $4 million in damages  to cover Smith & Nephew's lost profits from the infringement. Further damages, however, can't yet be decided because the jury's verdict was too vague, according to Judge Rya Zobel of the U.S. District Court for Massachusetts. In October 2013, Hologic  asked a federal judge in Massachusetts to revisit that loss . Last June, Judge Rya Zobel of the U.S. District Court for Massachusetts  upheld that decision  but found that any damages owed by Hologic to the British medical products giant couldn't yet be determined.

  • When was Interlace Medical founded?

    Interlace Medical was founded in 2005.

  • Where is Interlace Medical's headquarters?

    Interlace Medical's headquarters is located at 139 Newbury Street, Framingham.

  • What is Interlace Medical's latest funding round?

    Interlace Medical's latest funding round is Acquired.

  • How much did Interlace Medical raise?

    Interlace Medical raised a total of $26.25M.

  • Who are the investors of Interlace Medical?

    Investors of Interlace Medical include Hologic, New Leaf Venture Partners, Spray Venture Partners, HLM Venture Partners, Tekla Capital Management and 5 more.

  • Who are Interlace Medical's competitors?

    Competitors of Interlace Medical include Gynesonics, Endologix, Minimally Invasive Devices, Cabochon Aesthetics, Micrus Endovascular and 12 more.

You May Also Like

Uromedica Logo
Uromedica

Uromedica develops minimally invasive medical devices that treat unmet medical needs in the area of urinary incontinence and related disorders. Products (sold under the ACT and ProACT brands) are based on adjustable balloon technology. Conditions being treated are post-prostatectomy incontinence in men and stress incontinence in women (after earlier interventions have failed).

M
MitraLife

Developing minimally invasive methods and devices for treating congestive failure and cardiac valve diseasen(Acquired by ev3)

G
Gynesonics

Gynesonics is a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the Sonata System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata System uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata System, including the SMART Targeting Guide, enables the operator to target fibroids and optimize ablations within them. Sonata System's design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity.

N
Neurosonix

NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

O
Ouroboros Medical

Ouroboros Medical is a medical devices for minimally invasive spinal fusion

V
Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.